John F. Paolini - 16 Mar 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
Chief Medical Officer
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact for John F. Paolini
Issuer symbol
KNSA
Transactions as of
16 Mar 2022
Net transactions value
-$6,058
Form type
4
Filing time
18 Mar 2022, 16:39:18 UTC
Previous filing
07 Sep 2021
Next filing
23 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +1,725 +5.8% 31,725 16 Mar 2022 Direct F1
transaction KNSA Class A Common Share Tax liability $6,058 -598 -1.9% $10.13 31,127 16 Mar 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -1,725 -25% $0.000000 5,175 16 Mar 2022 Class A Common Share 1,725 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.